Roivant And Priovant Post More Than 48 Weeks To Treatment Failure For Brepocitinib In Non-Infectious Uveitis
The Catalyst Brief · Oct 22, 2026
Latest
Biotech Reverse Mergers Rebound To 27 Deals In 2026, As PIPE Financing Reshapes The Route Back To Public Markets
The Catalyst Brief · Oct 22, 2026
Myriad Genetics Sells Prenatal Health Business To Labcorp For $210 Million, Narrowing Its Focus To Cancer Care
The Catalyst Brief · Oct 22, 2026
Baxter Draws FDA Warning Over Cephalosporin Contamination Controls, Extending Multi-Site Oversight Concerns
The Catalyst Brief · Oct 22, 2026
Across the beats
- AI in Drug Discovery
Astellas Strikes More Than $400 Million AI Proteins Deal To Expand Early-Stage Discovery
The Catalyst Brief Oct 21, 2026 - Biopharmaceutical Industry
Roche Advances Fenebrutinib With 16% CDP Reduction, Building A Broader MS Case Ahead Of FDA Review
The Catalyst Brief Oct 22, 2026 - Biotech Innovation
Nature Study Programs Bacillus Subtilis With Plant-Made OMY, Enabling More Than 3,000-Fold Control Of Protein Synthesis
The Catalyst Brief Oct 21, 2026 - Healthcare Investment
Locust Walk Says China Reached 58% Of Licensing Deal Value In 2026, As U.S. Biotech M&A Hit $173 Billion Through Q3
The Catalyst Brief Oct 21, 2026 - Medical Technology
SCRS Launches Eagle Insights Dashboard To Score Sponsor And CRO Site Relationships
The Catalyst Brief Oct 21, 2026 - Regulatory & Policy
Nigeria Confirms Imported Ebola Case, Expanding DRC-Linked Outbreak To Fifth Country
The Catalyst Brief Oct 21, 2026
Most read
China Proposes Limits On Foreign Biopharma Platform Acquisitions, While Leaving Most Licensing Structures Untouched
Oct 16, 2026
Priority Health’s Collaboration with Color Health and Grail Aims to Transform Cancer Support for Employers
Jul 26, 2026
FDA Warns Eurofins Over Selective Recording That Compromised Microbiology Data
Oct 16, 2026
Vir Licenses Three T-Cell Engager Programs To Gilead In Deal Worth Up To $1.9 Billion
Oct 14, 2026
More coverage
Biopharmaceutical IndustryGSK Wins FDA Approval For Hibsago In Chronic Hepatitis B, Opening A Six-Month Functional-Cure Option
Hibsago is designed to reduce hepatitis B viral messenger RNA so some patients can stop treatment after up to 24 weeks and maintain viral control afterward. The decision gives GSK a first-in-class product, while also providing a commercial and technical validation point for Ionis’ antisense platform.
The Catalyst BriefOct 21, 2026
Biotech InnovationNature Study Retools Human AGO2 Into ALTER, A C-to-U RNA Editor That Tops Cas13 Comparators In HEK293T Cells
The work, published in Nature Biotechnology, describes AGO-led targeted editing of RNA, or ALTER, which fuses human AGO2 to a C-to-U deaminase and uses guide RNAs designed to favor binding over cleavage. The study positions a human-protein scaffold as a possible way to reduce some translation risks associated with nonhuman RNA editors, including delivery and immunogenicity concerns.
The Catalyst BriefOct 21, 2026
Regulatory & PolicyFDA Signals GenAI Medical Devices May Face Physician-Like Competency Review, As Draft Policy Moves Ahead
Rick Abramson, director of FDA's Digital Health Center of Excellence, said at The MedTech Conference that generative AI tools create an "unbounded evaluation space" that does not fit the agency's established software-as-a-medical-device framework. He also said the FDA intends to draft policy after reviewing more than 300 comments on its August discussion paper, with draft guidance expected on the course of months.
The Catalyst BriefOct 21, 2026
Healthcare InvestmentLycia Targets $227.8 Million IPO To Fund Two Food Allergy Programs And A Graves' Disease Study
Lycia plans to sell 14.7 million shares at $16 to $18 apiece, with net proceeds projected at $227.8 million if the final price lands at the midpoint. The filing gives an unusually explicit use-of-proceeds plan, tying the raise to phase 2 work for LCA-0061, LCA-0062 and LCA-0321.
The Catalyst BriefOct 20, 2026
Medical TechnologyEY Says Medtech Reached About $650 Billion In 2025 Revenue, With Growth Concentrated In Commercial Leaders
The 20th edition of EY's Pulse of the MedTech Industry report describes a sector that has recovered to a revenue high point despite trade, supply chain and investor pressures. Its central message is less celebratory than selective: record revenue and strong M&A are being driven by the companies that already know how to turn innovation into commercial performance.
The Catalyst BriefOct 20, 2026
AI in Drug DiscoveryAstraZeneca And Oracle Form AI Pact To Improve Clinical Trial Recruitment
The agreement focuses on selected use cases rather than a defined product launch, but it puts recruitment and trial operations at the center of AstraZeneca’s AI strategy. For Oracle, it is another attempt to position its healthcare data and cloud stack as infrastructure for biopharma development rather than only enterprise IT.
The Catalyst BriefOct 20, 2026
Biopharmaceutical IndustryPfizer Ends PF-06835375 Phase 2 In ITP, Leaving CXCR5 Program Direction Unclear
Pfizer confirmed that its phase 2 trial of PF-06835375 in primary immune thrombocytopenia has been terminated after enrolling 61 patients, according to the federal trials register. The company said the decision was business-based rather than safety-related, leaving investors and partners with an incomplete read on whether the asset or the CXCR5 mechanism still has a future inside the company.
The Catalyst BriefOct 20, 2026
Regulatory & PolicyTrump Orders NIH Women’s Health Division, Adding White House Task Force Amid Funding Strain
The initiative promises to streamline research into understudied diseases in women, improve diagnostics and treatment, and expand accountability around sex as a biological variable in NIH-funded work. Its policy significance lies in pairing a visible White House directive with an unclear operating model at a time when funding for women’s health research has already come under pressure.
The Catalyst BriefOct 20, 2026
Biopharmaceutical IndustryGenmab Faces A Darzalex Revenue Cliff As Petosemtamab And Rina-S Readouts Approach
Genmab executives and investors are framing the company’s next phase around a narrow set of oncology assets ahead of U.S. Darzalex patent expiry in 2029. The near-term question is less whether the cliff exists than whether upcoming data can compress the revenue gap fast enough to keep Genmab growing beyond it.
The Catalyst BriefOct 20, 2026
Biotech InnovationAbbVie Posts 30.2% Endoscopic Remission For ABBV-466, Topping Skyrizi Alone In Midphase Crohn’s Trial
In a 300-patient study, 30.2% of people on ABBV-466 achieved endoscopic remission at Week 12, compared with 21.3% on Skyrizi and 18.0% on trosunilimab alone. AbbVie is already running a larger 2,000-patient phase 2 program and has said interim looks could shape plans for phase 3 before the study ends.
The Catalyst BriefOct 20, 2026
AI in Drug DiscoveryLilly Signs Up To $1.1 Billion Metis Deal, Extending Its AI-Enabled Delivery Push
The collaboration centers on Metis’ AiLNP platform, which the company says combines a large lipid library, end-to-end screening and a lipid language model to design lipid nanoparticles. For Lilly, the deal fits a pattern: pairing AI investments with a series of delivery-focused partnerships and acquisitions as drug modalities become harder to deliver effectively.
The Catalyst BriefOct 20, 2026
Biopharmaceutical IndustryMerck KGaA Buys Silence Therapeutics For $1.1 Billion Enterprise Value, Adding A Phase 3-Ready PV siRNA Program
Merck KGaA said it will acquire Silence Therapeutics for $20 per share, with the companies describing the transaction as about $1.1 billion in enterprise value and about $1.3 billion in equity value. The strategic centerpiece is divesiran, which Silence is using as a springboard into Phase 3 in polycythemia vera after mid-stage data that put it near the front of an increasingly competitive field.
The Catalyst BriefOct 19, 2026